ArticleJournal of translational medicine2026
GluK1-containing kainate receptor-dependent long-term depression in the anterior cingulate cortex modulates chronic pain.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLong-term depression (LTD) is a pivotal form of synaptic plasticity in the central nervous system, yet its functions and cortical mechanisms remain unclear in chronic pain. Kainate receptors (KARs) are ionotropic glutamate receptors that regulate the release of both excitatory and inhibitory neurotransmitters in several brain areas, such as the anterior cingulate cortex (ACC), which is an important part of the brain for processing pain and emotions. KAR-dependent long-term potentiation (LTP) in the ACC has been proven to contribute to chronic pain. However, the existence of KAR-mediated LTD and its functional relevance to chronic pain remain unexplored.
methodsA multidisciplinary approach combining multi-channel field potential recording, whole-cell patch-clamp recording, and pharmacological assays was used to characterize KAR-mediated LTD in the ACC. The regulatory role of KAR-mediated LTD in chronic pain was evaluated using the spared nerve injury (SNI) mouse model, along with viral overexpression and knockdown techniques, as well as pharmacological administration of the KAR agonist ATPA.
resultsApplication of the KAR agonist kainic acid (KA) or the GluK1-selective agonist ATPA induced robust, dose-dependent LTD. The induction of LTD required the GluK1 subunit and L-type voltage-gated calcium channels but was independent of NMDA receptors. The Ca²⁺-activated PKA signaling pathway regulated this LTD, and presynaptic inhibition via GABA
conclusionsWe identified a novel form of KAR‑mediated LTD in the ACC that depends on GluK1‑containing KARs and the Ca²⁺‑activated PKA signaling pathway. This form of LTD is involved in modulating chronic pain. These findings suggest that GluK1-containing KARs in the ACC represent a potential intervention node for chronic pain, warranting further preclinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.